Evox partnership with Takeda Pharmaceutical for rare disease
Evox Therapeutics Ltd, a leading exosome therapeutics company, announced the signing of a rare disease-focused partnership with Takeda Pharmaceutical Company Limited. The... Read More
A case based understanding in co-development deal
In a Co-Development Agreement the intellectual property is typically licensed by the licensor to the alliance partner, and as well, the two... Read More
ProBiotix Health has signed a distribution licensing agreement with Velinoff Pharma in Bulgaria
UK-based life sciences business OptiBiotix Health said that its unit ProBiotix Health has signed a licensing agreement with Bulgarian pharmaceutical marketing company... Read More
Regeneron, Sanofi initiates clinical trial in Kevzara to treat COVID-19
Regeneron Pharmaceuticals and Sanofi have started a clinical programme evaluating Kevzara (sarilumab) in patients hospitalized with severe coronavirus (COVID-19) infection. Kevzara is... Read More
Cipla launches GLYCOHALE respule
Cipla has annouced the introduction of Glycohale Respules. This helps Cipla to strengthen the Respiratory portfolio. Glycopyrrolate inhalation is indicated for the... Read More
Sun Pharma launched “Take on acne” campaign
Sun Dermatology, a division of Sun Pharmaceutical Industries, Inc., USA, which is a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (together... Read More
AstraZeneca disinvest hypertension medicines to Atnahs Pharma
AstraZeneca divest its global commercial rights of Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide... Read More
Case Study: AstraZeneca to sublicense its global rights to Movantik
AstraZeneca has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is... Read More
Beximco and Mylan’s licensing deal for biosimilar in Bangladesh
Posted on28 Feb 2020
TagsBeximco Pharmaceuticals, licensing deal in pharma, Mylan, mylan licensing deal, Ogivri, trastuzumab
Comments0
Under the terms of the agreement, Beximco Pharma will receive the exclusive rights to launch Mylan’s portfolio of key monoclonal antibodies to... Read More
Insight on Hikma and Glenmark’s Exclusive Licensing Agreement for Commercialising Ryaltris Nasal Spray in the US
Posted on28 Feb 2020
Tagsdrug licensing, Glemark outlicensing, Glenmark, global pharma licensing deal, Hikma, inlicensing in pharma, Ryaltris
Comments0
Hikma Pharmaceuticals PLC and Glenmark Specialty S.A., a Swiss subsidiary of Glenmark Pharmaceuticals, a global innovative pharmaceutical company signed of an exclusive... Read More